Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy.
- DOI
- 10.1007/s10549-011-1558-3
- Published
- 2011 Jul
- Container
- Breast cancer research and treatment
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s10549-011-1558-3,
title = {Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy.},
author = {Lalisang RI and Erdkamp FL and Rodenburg CJ and Knibbeler-van Rossum CT and Nortier JW and van Bochove A and Slee PH and Voest EE and Wils JA and Wals J and Loosveld OJ and Smals AE and Blijham GH and Tjan-Heijnen VC and Schouten HC},
year = {2011},
journal = {Breast cancer research and treatment},
doi = {10.1007/s10549-011-1558-3},
url = {https://doi.org/10.1007/s10549-011-1558-3}
}RIS
TY - JOUR TI - Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy. AU - Lalisang RI AU - Erdkamp FL AU - Rodenburg CJ AU - Knibbeler-van Rossum CT AU - Nortier JW AU - van Bochove A AU - Slee PH AU - Voest EE AU - Wils JA AU - Wals J AU - Loosveld OJ AU - Smals AE AU - Blijham GH AU - Tjan-Heijnen VC AU - Schouten HC PY - 2011 JO - Breast cancer research and treatment DO - 10.1007/s10549-011-1558-3 UR - https://doi.org/10.1007/s10549-011-1558-3 ER -
APA
RI, L., FL, E., CJ, R., CT, K. R., JW, N., A, V. B., PH, S., EE, V., JA, W., J, W., OJ, L., AE, S., GH, B., VC, T., & HC, S. (2011). Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy.. Breast cancer research and treatment. https://doi.org/10.1007/s10549-011-1558-3
Source records
- pubmed · retrieved 2026-09-27T07:05:03.273Z